ECML/PKDD-2005 Workshop on Discovery Challenge Guide to the Hepatitis Dataset Shusaku TsumotoShoji Hirano Department.

Slides:

Advertisements

Similar presentations

Hepatocirrhosis Liver cirrhosis.

Advertisements

By: Lisa Iacopetti Angela Bravo Dominic Cruz

1. Interpret a positive HBeAg, Anti- HBcAg, and/or anti-HCV test.

Hepatitis C Treatment in Corrections: New Medicine, New Challenges

ADVERSE EVENT REPORTING

Wisconsin Department of Health Services Richard Miller Research Scientist Wisconsin Office of Health Informatics October 28, 2014 Matching Traffic Crash.

ECML/PKDD Discovery Challenges Petr Berka University of Economics, Prague

STUDY DESIGN CASE SERIES AND CROSS-SECTIONAL

Cross-border biomarker research of ovarian cancerCrossBiomark (HUSRB/1203/214/091) The project is co-financed by the European Union

UEMS Section of Gastroenterology Workhop BASL Proposals for Hepatology Training P. Michielsen Brussels, Nov. 29, 2000.

CPT Pathology and Laboratory

1. 2 Describe this picture? 3 4 Observations are affected by one’s background knowledge and what one wants to see We can describe it as “observations.

COHORT AND CASE-CONTROL DESIGNS Dr. N. Birkett, Department of Epidemiology & Community Medicine, University of Ottawa SUMMER COURSE: INTRODUCTION TO EPIDEMIOLOGY.

Liver Cirrhosis S. Diana Garcia

Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.

Pattern of Diabetes Emergencies among adult Yemeni Diabetic Patients Dr. Zayed Atef Faculty of Medicine Sana’a University.

HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,

Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.

P.O.W.E.R. The Power of Problem Solving. Perceive Apprehend decipher, deduce, discern, discover, distinguish, experience, gather, grasp, identify, know,

Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.

Knowledge and Practice of Blood Transfusion: A Survey of Nurses in Abu Dhabi, United Arab Emirates. Dr. Belal M. Hijji 1, Proff. Kader Parahoo 2, Proff.

Temporal Analysis of Platelet Data in Chronic Viral Hepatitis Dataset Shoji HiranoShusaku Tsumoto Department of Medical.

Patient Information - Viral Hepatitis B (HBV)

Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.

Cirrhosis Dr. Meg-angela Christi M. Amores. Cirrhosis a histopathologically defined condition – pathologic features consist of the development of fibrosis.

Agenda Introduction QUIZ Ancient History/Process Discussion items – Master syllabus – Class syllabus – Alternate Delivery syllabus Information Items.

CHAPTER ONE CHAPTER ONE INTRODUCTION TO PATHOPHYSIOLOGY. BY: BY: Dr. Uche Amaefuna-Obasi (MD).

May Issues and Visions of Health Information Manager (HIM) Education In JAPAN.

Pulse Oximetry Screening for Critical Congenital Heart Disease (CCHD): The Wisconsin Experience Region IV Genetics Meeting September 11, 2012 Sharon Fleischfresser.

Scott Renshaw, MD Department of Family Medicine Third Year Clerkship.

The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.

Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Pharmacy in Public Health: Describing Populations Course, date, etc. info.

Research in Health Informatics: Bangladesh Perspective Dr. Abu Sayed Md. Latiful Hoque Professor, Dept. of CSE, BUET Workshop on Health Data Analytics.

Treatment of HBV/HCV Coinfection

R. Papani, A. G. Duarte, Y-L. Lin, G. Sharma

Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP

Wei Wang, Long Jiang Zhang*, Guang Ming Lu*

NHP, Hanoi, Vietnam; and community clinics

No conflict of interest

Volume 46, Issue 3, Pages (March 2007)

The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.

SMOKING AND HISTOLOGICAL STAGE OF CHRONIC VIRAL HEPATITIS

Long-term impact of response to interferon-based therapy in patients with chronic HCV in relation to liver function, survival and cause of death Philip.

Diagnostic Services in Healthcare

Talking to Patients About HCV Treatment

Chronic viral hepatitis type B with “ground glass” cells

Chronic Hepatitis C Virus Infection

Hospital DB Requirements

Chapter 3 Fatty Liver Diseases 1 Alcoholic steatosis Case 3.1.

Modeling Medical Records of Diabetes using Markov Decision Processes

Evaluation of the Patient With HCV Infection

First needle marrow biopsy to diagnose a systemic illness

The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive.

Autoimmune hepatitis Journal of Hepatology

Introduction To Medical Technology

کتابهای تازه خریداری شده فن آوری اطلاعات سلامت 1397

Introduction to the Medical Laboratory

کتابهای خریداری شده فن آوری اطلاعات سلامت 1397

SELECTING RESEARCH DESIGN

Persistent histological inflammation in autoimmune hepatitis despite

LABORATORY OF PROCESS ENGINEERING

Introduction to epidemiology

Table 1. Most effective strategies to teach students to communicate the benefits and risks of medicines Strategy Considered most effective, %

Retrospective Post Payment Claim Review 2019 Q2

Course Course Director(s).

Venn diagram highlighting the reason(s) for an invalid liver stiffness evaluation (LSE) in the biopsied patients only. 56/153 patients had an invalid LSE.

Patient with histologically-proven ACLD

Presentation transcript:

ECML/PKDD-2005 Workshop on Discovery Challenge Guide to the Hepatitis Dataset Shusaku TsumotoShoji Hirano Department of Medical Informatics, Faculty of Medicine, Shimane University, Japan

Hepatitis Dataset: Basic Information Donators Dr. Katsuhiko Takabayashi and Dr. Hideto Yokoi Department of Medical Informatics, Chiba University Hospital, Japan Subjects 771 patients of type B and C chronic virus hepatitis who took examinations at Chiba University Hospital during 1982 and Contents Biopsy information: dates and results stage of fibrosis, virus activity Period of applying interferon therapy Laboratory Examinations Blood tests (Biochemical, Hematological, DNA), Urinalysis Basic information of patients MID (masked ID), Sex, Date of Birth

Hepatitis Dataset: Structure 7 tables in CSV format An MID (masked ID) is used to relate information in different table Description of Examinations (459) Stationary data Temporal data MID In-hospital Exam Results (1,565,876) Out-hospital Exam Results (31,040) Basic Patient Information (771) Interferon Administration Information (198) Biopsy Information (961) *Added on July 4, Results of Hematological Analysis (42,914) *

Goals of the Challenge Evaluate whether the laboratory examinations can be used to estimate the stage of liver fibrosis. If possible, it can be used as an alternate of invasive biopsy. Discover the differences in temporal patterns between hepatitis B and C. Evaluate whether the interferon therapy is effective or not. High-cost therapy; but it is not effective for all patients. Can we forecast its effectiveness in advance using the results of laboratory examinations ? Validate the following hypothesis regarding GOT and GPT. (GOT or GPT) x (time) = (stage of liver fibrosis)